Skip to main content
SpringerLink
Log in

Erlotinib

  • Chapter
  • First Online:
Small Molecules in Oncology

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 211))

Abstract

The epidermal growth factor receptor (EGFR) has been implicated in a multiplicity of cancer-related signal transduction pathways like cellular proliferation, adhesion, migration, neoangiogenesis and apoptosis inhibition, all of which are important features of cancerogenesis and tumour progression. Its tyrosine kinase activity plays a central role in mediating these processes and has been intensely studied to exploit it as a therapeutic target. Inhibitors of this pathway have been developed and assessed in trials with significant efficacy in clinical applications. The current review focuses in particular on the clinical data of EGFR tyrosine kinase inhibition in different tumour entities, preferably non-small cell lung cancer and pancreatic cancer with emphasis to the approved small molecule erlotinib. Its clinical applications, evidence-based efficacy and toxicity as well as predictive markers of response are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Alroy I, Yarden Y (1997) The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 410:83–86

    Article  CAS  PubMed  Google Scholar 

  • Bezjak A, Tu D, Seymour L et al (2006) Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study Br. 21. J Clin Oncol 24:3831–3837

    Article  CAS  PubMed  Google Scholar 

  • Birk D, Gansauge F, Gansauge S (1999) Serum and correspondent tissue measurements of epidermal growth factor (EGF) and epidermal growth factor receptor (EGF-R). Clinical relevance in pancreatic cancer and chronic pancreatitis. Int J Pancreatol 25:89–96

    Article  CAS  PubMed  Google Scholar 

  • Boeck S, Hausmann A, Reibke R et al (2007) Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. Anticancer Drugs 18:1109–1111

    Article  CAS  PubMed  Google Scholar 

  • Brabender J, Danenberg KD, Metzger R et al (2001) Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 7:1850–1855

    PubMed  CAS  Google Scholar 

  • Bramhall SR, Schulz J, Nemunaitis J (2002) A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87:161–167

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Buckley AF, Burgart LJ, Sahai V et al (2008) Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am J Clin Pathol 129:245–251

    Article  PubMed  Google Scholar 

  • Burris HA 3rd, Moore MJ, Andersen J (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413

    Article  CAS  PubMed  Google Scholar 

  • Cedrés S, Prat A, Martínez P et al (2009) Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib. Lung Cancer 66:257–261

    Article  PubMed  Google Scholar 

  • Chen G, Fen J, Zhou C et al (2013) Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR-mutation positive non-small cell lung cancer (NSCLC). Ann Oncol 24:1615–1622

    Article  CAS  PubMed  Google Scholar 

  • Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34

    Article  CAS  PubMed  Google Scholar 

  • Chiang D, Villanueva A, Peix J (2008) Focal VEGFA amplifications and molecular classification of hepatocellular carcinoma. Cancer Res 68:6779–6788

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Crinó L, Cappuzzo F, Zatloukal P et al (2008) Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 26:4253–4260

    Article  CAS  PubMed  Google Scholar 

  • Dudek AZ, Kmak KL, Koopmeiners J, Keshtgarpour M (2006) Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Lung Cancer 51:89–96

    Article  PubMed  Google Scholar 

  • Duffy A, Kortmansky J, Schwartz GK et al (2008) A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann Oncol 19:86–91

    Article  CAS  PubMed  Google Scholar 

  • El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745–750

    Article  CAS  PubMed  Google Scholar 

  • Epelbaum R, Schnaider J, Gluzman A (2007) Erlotinib as a single-agent therapy in patients with advanced pancreatic cancer. In: ASCO gastrointestinal cancer symposium, Orlando, FL, 19–21 Jan 2007

    Google Scholar 

  • Fukuoka M, Wu YL, Thongprasert S et al (2011) Biomarker analyses and final overall survival results from a phase III randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small cell lung cancer in Asia (IPASS). J Clin Oncol 29:2866–2874

    Article  CAS  PubMed  Google Scholar 

  • Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237–2246

    Article  CAS  PubMed  Google Scholar 

  • Gao JW, Zhan P, Qiu XY, Jin JJ et al (2017) Erlotinib-based doublet targeted therapy versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis from 24 randomized controlled trials. Oncotargets 8:73258–73270

    Google Scholar 

  • Garassino MC, Martelli O, Broggini M et al (2013) Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 14:981–988

    Google Scholar 

  • Garon EB, Reck M, Paz-Ares L et al (2017) Treatment rationale and study design for the RELAY study: a multicenter, randomized, double-blind study of erlotinib with ramucirumab or placebo in patients with epidermal growth factor receptor mutation-positive metastatic non-small-cell lung cancer. Clin Lung Cancer 18:96–99

    Article  CAS  PubMed  Google Scholar 

  • Gatzemeier U, Pluzanska A, Szczesna A et al (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva lung cancer investigation trial. J Clin Oncol 25:1545–1552

    Article  CAS  PubMed  Google Scholar 

  • Giaccone G, Herbst RS, Manegold C et al (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol 22:777–784

    Google Scholar 

  • Herbst RS, Prager D, Hermann R et al (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892–5899

    Article  CAS  PubMed  Google Scholar 

  • Huether A, Hopfner M, Sutter AP et al (2006) Signaling pathways involved in the inhibition of epidermal growth factor receptor by erlotinib in hepatocellular cancer. World J Gastroenterol 12:5160–5167

    PubMed  PubMed Central  CAS  Google Scholar 

  • Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341–354

    Article  CAS  Google Scholar 

  • Iannitti D, Dipetrillo T, Akerman P (2005) Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. Am J Clin Oncol 28:570–575

    Article  CAS  PubMed  Google Scholar 

  • Kato T, Seto T, Nishio M et al (2017) Erlotinib plus bevacizumab phase II study in patients with advanced non-small-cell lung cancer (JO25567): updated safety results. Drug Saf 41:229–237

    Google Scholar 

  • Kim ES, Hirsh V, Mok T et al (2008) Gefitinib versus docetaxel in previously treated non-small cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372:1809–1818

    Article  CAS  PubMed  Google Scholar 

  • Kindler H, Niedzwiecki D, Hollis D et al (2010) Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28:3617–3622

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kris MG, Natale RB, Herbst RS et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149–2158

    Article  CAS  PubMed  Google Scholar 

  • Kulke MH, Blaszkowsky LS, Ryan DP et al (2007) Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 25:4787–4792

    Article  CAS  PubMed  Google Scholar 

  • Llovet JM, Brú C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338

    Article  CAS  PubMed  Google Scholar 

  • Llovet JM, Bruix J (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48:1312–1327

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Llovet JM, Ricci S, Mazzaferro V et al, SHARP Investigators Study Group (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390

    Google Scholar 

  • Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139

    Article  CAS  PubMed  Google Scholar 

  • Lynch TJ Jr, Kim ES, Eaby B (2007) Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12:610–621

    Article  CAS  PubMed  Google Scholar 

  • Marchetti A, Martella C, Felicioni L et al (2005) EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23:857–865

    Article  CAS  PubMed  Google Scholar 

  • Mok T, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957

    Article  CAS  PubMed  Google Scholar 

  • Moore MJ, Goldstein D, Hamm J (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966

    Article  CAS  PubMed  Google Scholar 

  • Moore MJ, Hamm J, Dancey J (2003) Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY12–9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21:3296–3302

    Article  CAS  PubMed  Google Scholar 

  • Natale RB (2004) Effects of ZD1839 (Iressa, gefitinib) treatment on symptoms and quality of life in patients with advanced non-small cell lung cancer. Sem Oncol 31(3 suppl 9):23–30

    Article  CAS  Google Scholar 

  • Neuhaus P, Riess H, Post S et al (2008) CONKO-001: final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J Clin Oncol 26:abstr LBA4504

    Google Scholar 

  • Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37(suppl 4):S9–S15

    Article  CAS  PubMed  Google Scholar 

  • Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500

    Article  CAS  PubMed  Google Scholar 

  • Parkin DM, Bray F, Ferlay J (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108

    Article  PubMed  Google Scholar 

  • Pao W, Miller V, Zakowski M et al (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306–13311

    Article  CAS  PubMed  Google Scholar 

  • Pao W, Miller VA (2005) Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small cell lung cancer: current knowledge and future directions. J Clin Oncol 23:2556–2568

    Article  CAS  PubMed  Google Scholar 

  • Pelzer U, Kubica K, Stieler J et al (2008) A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 26 (suppl): abstr 4508

    Google Scholar 

  • Pérez-Soler R, Chachoua A, Hammond LA et al (2004) Determants of tumour response and survival with erlotinib in patients with non-small-cell lung cancer: a randomized trial. J Clin Oncol 22:3238–3247

    Article  CAS  PubMed  Google Scholar 

  • Pérez-Soler R (2006) Rash as a surrogate marker for efficacy of epidermal growth factor inhibitors in lung cancer. Clin Lung Cancer 8(suppl 1):S7–14

    Article  PubMed  Google Scholar 

  • Philip PA, Benedetti J, Fenoglio-Preiser C (2007) Phase III study of gemcitabine (G) plus cetuximab (C) versus gemcitabine in patients (Pts) with locally advanced or metastatic pancreatic adenocarcinoma (PC) SWOG S0205 study. J Clin Oncol 25(suppl 18): LBA4509

    Google Scholar 

  • Philip PA, Mahoney MR, Allmer C (2005) Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23:6657–6663

    Article  CAS  PubMed  Google Scholar 

  • Ramalingam SS, Yang JC, Lee CK et al (2017) Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. J Clin Oncol 36:841–849

    Google Scholar 

  • Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239–246

    Article  CAS  PubMed  Google Scholar 

  • Schneider G, Hamacher R, Eser S et al (2008) Molecular biology of pancreatic cancer—new aspects and targets. Anticancer Res 28(3A):1541–1550

    PubMed  CAS  Google Scholar 

  • Saif MW, Merikas I, Tsimboukis S et al (2008) Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients. JOP 9:267–274

    PubMed  Google Scholar 

  • Salomon DS, Brandt R, Ciardiello F et al (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183–232

    Article  CAS  PubMed  Google Scholar 

  • Sandler AB (2006) Nondermatologic adverse events associated with anti-EGFR therapy. Oncology 20(5 Suppl 2):35–40

    PubMed  Google Scholar 

  • Seto T, Kato T, Nishio M et al (2014) Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol 15:1236–1244

    Article  CAS  PubMed  Google Scholar 

  • Shapiro J, Marshall J, Karasek P (2005) G17DT + gemcitabine (Gem) versus placebo + Gem in untreated subjects with locally advanced, recurrent, or metastatic adenocarcinoma of the pancreas: results of a randomized, double-blind, multinational, multicenter study. J Clin Oncol 23(suppl 16):4012

    Article  Google Scholar 

  • Shepherd FA, Pereira JR, Ciuleanu T et al for the National Cancer Institute of Canada Clinical Trails Group (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132

    Google Scholar 

  • Soria JC, Felip E, Cobo M et al (2015) Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol 16:897–907

    Article  CAS  PubMed  Google Scholar 

  • Sultana A, Smith CT, Cunningham D et al (2007) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 20:2607–2615

    Article  Google Scholar 

  • Tang PA, Tsao MS, Moore MJ (2006) A review of erlotinib and its clinical use. Expert Opin Pharmacother 7:177–193

    Article  CAS  PubMed  Google Scholar 

  • Thomas MB, Chadha R, Glover K (2007) Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110:1059–1067

    Article  CAS  PubMed  Google Scholar 

  • Thomas MB, Morris JS, Chadha R et al (2009) Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 27:843–850

    Article  CAS  PubMed  Google Scholar 

  • Thongprasert S, Duffield E, Saijo N et al (2011) Health-related quality-of-life in a randomized first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). J Thorac Oncol 6:1872–1880

    Article  PubMed  Google Scholar 

  • Tsao MS, Sakurada A, Cutz JC et al (2005) Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med 353:133–144

    Article  CAS  PubMed  Google Scholar 

  • Van Cutsem E, Van de Velde H, Karasek P (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430–1438

    Article  CAS  PubMed  Google Scholar 

  • Van Cutsem E, Vervenne WL, Bennouna J et al (2009) Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: results from the AViTA study. In: ASCO gastrointestinal cancers symposium, A117

    Google Scholar 

  • Villanueva A, Newell P, Chiang D (2007) Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 27:55–76

    Article  CAS  PubMed  Google Scholar 

  • Wacker B, Nagrani T, Weinberg J et al (2007) Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 13:3913–3921

    Article  CAS  PubMed  Google Scholar 

  • Yang JC, Ahn MJ, Kim DW et al (2017) Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. J Clin Oncol 35:1288–1296

    Article  CAS  PubMed  Google Scholar 

  • Xiong HQ, Abbruzzese JL (2002) Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol 29(14 suppl):31–37

    Article  CAS  PubMed  Google Scholar 

  • Zhou C, Wu YL, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomized phase 3 trial. Lancet Oncol 12:735–742

    Article  CAS  PubMed  Google Scholar 

  • Zhu C-Q, da Cunha Santos G, Ding K et al (2008) Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study Br. 21. J Clin Oncol 26:4268–4275

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinic for Thoracic Diseases, University of Heidelberg, Röntgenstr. 1, 69126, Heidelberg, Germany

    Martin Steins & Michael Thomas

  2. Department of Oncology, Gastroenterology and Internal Medicine, Städtische Kliniken Esslingen, Hirschlandstr. 97, 73730, Esslingen, Germany

    Michael Geißler

Authors
  1. Martin Steins
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Geißler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Martin Steins or Michael Thomas .

Editor information

Editors and Affiliations

  1. MOLIT Institute, Cancer Center Heilbronn-Franken, SLK-Clinics, Heilbronn, Baden-Württemberg, Germany

    Uwe M. Martens

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Steins, M., Thomas, M., Geißler, M. (2018). Erlotinib. In: Martens, U. (eds) Small Molecules in Oncology. Recent Results in Cancer Research, vol 211. Springer, Cham. https://doi.org/10.1007/978-3-319-91442-8_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-91442-8_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-91441-1

  • Online ISBN: 978-3-319-91442-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation